Literature DB >> 28400428

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Sonja Ludwig1,2,3, Theofanis Floros4, Marie-Nicole Theodoraki2,5, Chang-Sook Hong1, Edwin K Jackson6, Stephan Lang3, Theresa L Whiteside7,2.   

Abstract

Purpose: Head and neck cancers (HNCs) often induce profound immunosuppression, which contributes to disease progression and interferes with immune-based therapies. Body fluids of patients with HNC are enriched in exosomes potentially engaged in negative regulation of antitumor immune responses. The presence and content of exosomes derived from plasma of patients with HNC are evaluated for the ability to induce immune dysfunction and influence disease activity.Experimental Design: Exosomes were isolated by size-exclusion chromatography from plasma of 38 patients with HNC and 14 healthy donors. Morphology, size, numbers, and protein and molecular contents of the recovered exosomes were determined. Coculture assays were performed to measure exosome-mediated effects on functions of normal human lymphocyte subsets and natural killer (NK) cells. The results were correlated with disease stage and activity.
Results: The presence, quantity, and molecular content of isolated, plasma-derived exosomes discriminated patients with HNC with active disease (AD) from those with no evident disease (NED) after oncologic therapies. Exosomes of patients with AD were significantly more effective than exosomes of patients with NED in inducing apoptosis of CD8+ T cells, suppression of CD4+ T-cell proliferation, and upregulation of regulatory T-cell (Treg) suppressor functions (all at P < 0.05). Exosomes of patients with AD also downregulated NKG2D expression levels in NK cells.Conclusions: Exosomes in plasma of patients with HNC carry immunosuppressive molecules and interfere with functions of immune cells. Exosome-induced immune suppression correlates with disease activity in HNC, suggesting that plasma exosomes could be useful as biomarkers of HNC progression. Clin Cancer Res; 23(16); 4843-54. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28400428      PMCID: PMC5559308          DOI: 10.1158/1078-0432.CCR-16-2819

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

2.  Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.

Authors:  Malgorzata Czystowska; Miroslaw J Szczepanski; Marta Szajnik; Karen Quadrini; Harvey Brandwein; John W Hadden; Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2010-12-23       Impact factor: 6.968

3.  Isolation of biologically-active exosomes from human plasma.

Authors:  Laurent Muller; Chang-Sook Hong; Donna B Stolz; Simon C Watkins; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2014-06-18       Impact factor: 2.303

Review 4.  Tumor-Derived Exosomes and Their Role in Cancer Progression.

Authors:  Theresa L Whiteside
Journal:  Adv Clin Chem       Date:  2016-04-07       Impact factor: 5.394

5.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

7.  Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Authors:  Dejan Baskic; Lazar Vujanovic; Nebojsa Arsenijevic; Theresa L Whiteside; Eugene N Myers; Nikola L Vujanovic
Journal:  Head Neck       Date:  2012-04-05       Impact factor: 3.147

8.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.

Authors:  Jeong Whun Kim; Eva Wieckowski; Douglas D Taylor; Torsten E Reichert; Simon Watkins; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

Review 9.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).

Authors:  Theresa L Whiteside
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

10.  The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC.

Authors:  Malgorzata Czystowska; William Gooding; Miroslaw J Szczepanski; Andres Lopez-Abaitero; Robert L Ferris; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2012-12-19       Impact factor: 12.531

View more
  119 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

2.  Isolation and Analysis of Tumor-Derived Exosomes.

Authors:  Nils Ludwig; Chang-Sook Hong; Sonja Ludwig; Juliana H Azambuja; Priyanka Sharma; Marie-Nicole Theodoraki; Theresa L Whiteside
Journal:  Curr Protoc Immunol       Date:  2019-12

Review 3.  The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2018-11-09       Impact factor: 5.225

Review 4.  Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases.

Authors:  J Meldolesi
Journal:  Clin Exp Immunol       Date:  2019-03-11       Impact factor: 4.330

5.  Role of extracellular vesicles in stem cell biology.

Authors:  Stefania Bruno; Giulia Chiabotto; Enrica Favaro; Maria Chiara Deregibus; Giovanni Camussi
Journal:  Am J Physiol Cell Physiol       Date:  2019-05-15       Impact factor: 4.249

6.  Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.

Authors:  M-N Theodoraki; T K Hoffmann; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2018-03-12       Impact factor: 4.330

Review 7.  Exosomes: nanodust?

Authors:  L Muller
Journal:  HNO       Date:  2020-01       Impact factor: 1.284

Review 8.  Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.

Authors:  Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson
Journal:  Stem Cells Dev       Date:  2020-01-30       Impact factor: 3.272

Review 9.  Exosomes: Definition, Role in Tumor Development and Clinical Implications.

Authors:  Alberto Carretero-González; Irene Otero; Lucía Carril-Ajuria; Guillermo de Velasco; Luis Manso
Journal:  Cancer Microenviron       Date:  2018-05-03

Review 10.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.